Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 7/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704498 | 1.00 | F10 (0.45) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7710023 | 0.93 | F10 (0.45) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7710018 | 0.93 | F10 (0.45) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7704370 | 0.92 | F10 (0.49) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7704368 | 0.92 | F10 (0.49) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7710459 | 0.90 | F10 (0.48) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7710463 | 0.90 | F10 (0.48) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6701819 | 0.90 | F10 (0.54) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7704253 | 0.89 | F10 (0.47) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7704256 | 0.89 | F10 (0.47) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072842-A1 | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent | PHARMACIA & UPJOHN COMPANY | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072842-A1 | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent | GMDS, PGLS, DDOST | F10 4107/4885MAOA 3409/4885MAOB 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.